Tails from the Peak District: adjusted censored mixture models of EQ-5D health state utility values
暂无分享,去创建一个
[1] Paul Kind,et al. A social tariff for EuroQol: results from a UK general population survey , 1995 .
[2] John Brazier,et al. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? , 2009, Health and quality of life outcomes.
[3] Rachelle Buchbinder,et al. Functional Status and Health-related Quality of Life Assessment in Patients with Rheumatoid Arthritis , 2001 .
[4] Aki Tsuchiya,et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[5] Alan Brennan,et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. , 2008, Arthritis and rheumatism.
[6] Andrew Briggs,et al. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences , 2010, The European Journal of Health Economics.
[7] A. Brennan,et al. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden , 2004, Annals of the rheumatic diseases.
[8] Martin J Buxton,et al. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease , 2010, Health and quality of life outcomes.
[9] Geoffrey J. McLachlan,et al. Finite Mixture Models , 2019, Annual Review of Statistics and Its Application.
[10] J. Tobin. Estimation of Relationships for Limited Dependent Variables , 1958 .
[11] A. Silman,et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. , 2002, Rheumatology.
[12] P. Kind,et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). , 1997, British journal of rheumatology.
[13] Peter Lindgren,et al. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. , 2002, Arthritis and rheumatism.
[14] P Tugwell,et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. , 2008, Arthritis and rheumatism.
[15] Allan Wailoo,et al. Multilevel modelling of cost data: an application to thrombolysis and primary angioplasty in the UK NHS , 2010 .
[16] Peter Lindgren,et al. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden , 2009, International Journal of Technology Assessment in Health Care.
[17] Peter C Austin,et al. A comparison of methods for analyzing health-related quality-of-life measures. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] S A Marion,et al. Not all "quality-adjusted life years" are equal. , 2007, Journal of clinical epidemiology.
[19] Liang Li,et al. Some methodological issues with the analysis of preference-based EQ-5D index score , 2009, Health Services and Outcomes Research Methodology.
[20] Wojciech W. Charemza,et al. NEW DIRECTIONS IN ECONOMETRIC PRACTICE , 1992 .
[21] P Barton,et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. , 2006, Health technology assessment.
[22] William L. Goffe,et al. SIMANN: FORTRAN module to perform Global Optimization of Statistical Functions with Simulated Annealing , 1992 .
[23] B. Muthén,et al. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study , 2007 .
[24] M. Escobar,et al. The use of the Tobit model for analyzing measures of health status , 2004, Quality of Life Research.
[25] V. Farewell,et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[26] R. Goeree,et al. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[27] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[28] N. Cooper. Economic burden of rheumatoid arthritis: a systematic review. , 2000, Rheumatology.
[29] Sandro Ridella,et al. Minimizing multimodal functions of continuous variables with the “simulated annealing” algorithmCorrigenda for this article is available here , 1987, TOMS.
[30] Richard Grieve,et al. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. , 2006, Journal of health economics.
[31] Albert W Wu,et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. , 2007, Health services research.
[32] Aki Tsuchiya,et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.
[33] Mónica Hernández. Alava,et al. Growth dynamics : an empirical investigation of output growth using international data , 2002 .